[Federal Register: September
20, 2001 (Volume 66, Number 183)]
[Notices]
[Page 48424-48425]
From the Federal Register Online via GPO Access
[wais.access.gpo.gov]
[DOCID:fr20se01-39]
-----------------------------------------------------------------------
DEPARTMENT OF
COMMERCE
Foreign-Trade Zones
Board
Docket 37-2001
Foreign-Trade Zone
72--Indianapolis Airport Authority Expansion
of Facilities and Manufacturing Authority--Subzone 72B, Eli Lilly
and
Company Plants (Pharmaceuticals) Indianapolis, Indiana,
Area
An
application has been submitted to the Foreign-Trade Zones
Board
(the Board) by the Indianapolis Airport Authority, grantee of FTZ
72,
pursuant to Sec. 400.32(b)(1) of the Board's regulations (15 CFR
part
400), requesting authority on behalf of Eli Lilly and Company
(Lilly),
to add FTZ manufacturing capacity and to expand the scope of
manufacturing authority under zone procedures at Subzone 72B, at
the
Lilly plants in the Indianapolis, Indiana, area. It was formally
filed
on September 13, 2001.
Subzones 72B, 72C, and 72D were approved by the
Board in 1985
(Board Order 309, 50 FR 31404, 8/2/85). The subzones were
consolidated
into one subzone and redesignated Subzone 72B in 1996
(A(27f)-1-96).
The facilities (14,300 employees) are used to manufacture,
test,
package, and warehouse human and animal health products.
Subzone 72B currently consists of three sites
(366 buildings,
6,709,300 sq. ft., 1,456 acres) in the Indianapolis, Indiana, port
of
entry area. The applicant is proposing to expand Subzone 72B
which
would then consist of 491
buildings of 21,905,916 square feet on 3,439
acres.
Site 1 (5 parcels in Marion County, Indianapolis
area), currently
consists of 60 buildings containing 5,029,300 sq. ft. on 260
acres.
Lilly is now proposing to add 125 buildings and 13,544,928 sq. ft.,
and
102 acres. Site 1 would then consist of 185 buildings of 18,574,228
sq.
ft. on 359 acres.
Site 2 currently consists of 140 buildings,
1,170,000 sq. ft. on
449 acres on a single parcel located at 2010 Eli Lilly Road,
Shadeland,
Indiana. Lilly is proposing to add 363,687 square feet to existing
and
future buildings and add 1,877 acres. Site 2 would then total
140
buildings of 1,533,687 sq. ft. on 2,326 acres.
Site 3, located at State Road 63, Clinton,
Indiana, is currently
approved for 166 buildings of 510,000 sq. ft. on 747 acres.
The
proposed expansion would add 1,288,001 sq. ft. to existing and
future
buildings and add 4 acres. Site 3 would then consist of 166
buildings,
1,798,001 sq. ft. on 751 acres.
The application also requests to expand and
clarify the scope of
authority for manufacturing
activity conducted under FTZ procedures at
Subzone 72B to include additional general categories of inputs
that
have recently been approved by the Board for other
pharmaceutical
plants. They include gums, resins, starches, glycerol,
vegetable
extracts, mineral oils, chemically pure sugars, empty capsules
for
pharmaceutical use, protein concentrates, prepared animal feed,
sodium
chloride, natural magnesium phosphates and carbonates, gypsum,
talc,
anhydrite and plasters, petroleum jelly, paraffin and waxes,
sulfuric
acid, phosphoric acid, other inorganic acids or compounds of
nonmetals,
ammonia, fluorides, sulfates, sulfites, phosphates, cyanides,
silicates, hydroxides, zinc oxide, titanium oxide, hydrazine
and
hydroxylamine, carbonates, salts of oxometallic acids,
radioactive
chemical elements, compounds of rare earth metals,
hydrocarbons,
acyclic hydrocarbons, alcohols, phenols, derivatives of phenols
or
peroxides, ethers, epoxides, aldehydes, ketone function
compounds,
mono- and
[[Page 48425]]
polycarboxylic acids,
phosphoric esters; amine-, carboxymide, nitrile-
and oxygen-function compounds; heterocyclic compounds,
sulfonamides,
acetals and hemiacetals, phosphoric esters and their salts,
diazo-
compounds, glands for therapeutic uses, insecticides,
rodenticides,
fungicides and herbicides, fertilizers, vitamins, hormones,
antibiotics, gelatins, enzymes, pharmaceutical glaze, essential
oils,
albumins, gelatins, activated carbon, residual lyes, acrylic
polymers,
color lakes, soaps and detergents, wadding, gauze and
bandages,
pharmaceutical glaze, hair preparations, lubricating
preparations,
albumins, prepared glues and adhesives, catalytic
preparations,
diagnostic or laboratory reagents, prepared binders, polymers
of
ethylene, acrylic polymers, self-adhesive plates and sheets,
other
articles of vulcanized rubber, plastic cases, cardboard boxes,
printed
books, brochures and similar printed matter, printing ink,
carboys,
bottles, and flasks, stoppers, caps, and lids, aluminum foil,
tin
plates and sheets, taps, cocks and valves, and medical instruments
and
appliances.
FTZ procedures would exempt Lilly from Customs
duty payments on the
foreign components used in export activity. On its domestic sales,
the
company would be able to elect the duty rates that apply to
finished
products (primarily duty-free for finished pharmaceuticals and up
to
14.2% for intermediates) for the foreign materials noted above
(duty
rates ranging from duty-free to 14.5%). The application indicates
that
the expanded use of FTZ procedures will help improve Lilly's
international competitiveness.
Public comment on the application is invited
from interested
parties. Submissions (original and three copies) shall be addressed
to
the Board's Executive Secretary at the address below. The
closing
period for their receipt is November 5, 2001. Rebuttal comments
in
response to material submitted during the foregoing period may
be
submitted during the subsequent 5-day period (to November 9,
2001).
Copies of the applications will be available for
public inspection
at the following locations:
U.S. Department of Commerce,
Export Assistance Center, 11405 N.
Pennsylvania Street, Suite 106, Carmel, Indiana 46032
Office of the Executive Secretary, Foreign-Trade Zones Board,
Room
4008, U.S. Department of Commerce, 14th Street & Pennsylvania
Avenue,
NW, Washington, DC 20230
Dated:
September 13, 2001.
Dennis Puccinelli,
Executive Secretary.
[FR Doc. 01-23455 Filed 9-19-01; 8:45 am]
BILLING CODE 3510-DS-P